cropped-DCHead03041
cropped-DCHead03041

press to zoom
you are what you eat
you are what you eat

press to zoom

press to zoom
cropped-DCHead03041
cropped-DCHead03041

press to zoom
1/6
Dr Chelson, Naturopathic Physician

DeboraChelson NMD PC

Naturopathic Physician, Wholistic Medicine

  • Home

  • My Practice

    • My Services
    • My Philosophy
    • Naturopathic Medicine
    • Naturopathic Physician
    • Testimonials
  • Patient Services

    • Patient Forms
    • Supplements
    • Labs
  • Articles & Recipes

  • Contact

  • Blog

  • Members

  • More

    Use tab to navigate through the menu items.
    To see this working, head to your live site.
    • Categories
    • All Posts
    • My Posts
    doctor06
    Nov 11, 2020
      ·  Edited: Nov 11, 2020

    Low dose Naltrexone for remission in inflammatory bowel disease patients

    in Disease & Modern Medicine

    This was a clinical trial with patients with Crohn’s disease, Ulcerative colitis, and IBD, not in remission, and not responding to conventional therapy was offered to initiate LDN as concomitant treatment. In total 47 IBD patients prescribed LDN were followed prospectively for 12 weeks.


    Results: Low dose Naltrexone induced clinical improvement in 74.5%, and remission in 25.5% of patients. Naltrexone improved wound healing and reduced ER ( endoplasmic reticulum) stress induced by Tunicamycin, lipopolysaccharide, or bacteria in epithelial barriers. Inflamed mucosa from IBD patients showed high ER stress levels, which was reduced in patients treated with LDN. Conclusions: Naltrexone directly improves epithelial barrier function by improving wound healing and reducing mucosal ER stress levels. Low dose Naltrexone treatment is effective and safe and could be considered for the treatment of therapy refractory IBD patients.


    Article https://pubmed.ncbi.nlm.nih.gov/29523156/


    0 comments
    0
    0 comments

    © 2017 by Debora Chelson. Proudly created with Wix.com